Local Cytokine Expression Profiling in Patients with Specific Autoimmune Uveitic Entities

References

• Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, et al. The Cytokine Interleukin-6 and the Chemokines CCL20 and CXCL13 are novel biomarkers of specific endogenous uveitic entities. Invest Ophthalmol Vis Sci. 2016;57:4606–4613. doi:10.1167/iovs.16-19758.
   PubMed Web of Science ®Google Scholar
• El-Asrar AM, Al-Obeidan SS, Kangave D, et al. CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Immunobiology. 2011;216:1004–1009. doi:10.1016/j.imbio.2011.03.007.
   PubMed Web of Science ®Google Scholar
• El-Asrar AM, Struyf S, Kangave D, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol. 2011;139:177–184. doi:10.1016/j.clim.2011.01.014.
   PubMed Web of Science ®Google Scholar
• El-Asrar AM, Berghmans N, Al-Obeidan SA, et al. Differential CXC and CX3C chemokine expression profiles in aqueous humor of patients with specific endogenous uveitic entities. Invest Ophthamol Vis Sci. 2018;59:2222–2228. doi:10.1167/iovs.17-23225.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, et al. The CC chemokines CCL8, CCL13 and CCL20 are local inflammatory biomarkers of HLA-B27-associated uveitis. Acta Ophthalmol. 2019;97:e122–e128. doi:10.1111/aos.13835.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, et al. Expression of interleukin (IL)-10 family cytokines in aqueous humour of patients with specific endogenous uveitic entities: elevated levels of IL-19 in human leucocyte antigen-B27-associated uveitis. Acta Ophthalmol. 2019 Feb 13. DOI:10.1111/aos.14039.
   Web of Science ®Google Scholar
• Romagnani S. The Th1/Th2 paradigm. Immunol Today. 1997;18:263–266.
   PubMedGoogle Scholar
• Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787–793. doi:10.1038/383787a0.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785–796. doi:10.1016/j.ophtha.2013.09.048.
   PubMed Web of Science ®Google Scholar
• Al Rashidi S, Al Fawaz A, Kangave D, et al. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab. Ocul Immunol Inflamm. 2013;21:468–474. doi:10.3109/09273948.2013.779727.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenç V, et al. Targeting interleukin-6 in autoimmune uveitis. Autoimmun Rev. 2017;16:1079–1089. doi:10.1016/j.autrev.2017.08.002.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenç V, Sainz de la Maza M, Adán A. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121:2380–2386. doi:10.1016/j.ophtha.2014.06.050.
   PubMed Web of Science ®Google Scholar
• Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood. 1993;81:2844–2853.
   PubMed Web of Science ®Google Scholar
• Ogawa M, Matsunaga T. Humoral regulation of hematopoietic stem cells. Ann N Y Acad Sci. 1999;872:17–24.
   PubMed Web of Science ®Google Scholar
• Nakashima K, Taga T. gp130 and the IL-6 family of cytokines: signaling mechanisms and thrombopoietic activities. Semin Hematol. 1998;35:210–221.
   PubMed Web of Science ®Google Scholar
• Seita J, Asakawa M, Ooehara J, et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood. 2008;111:1903–1912. doi:10.1182/blood-2007-06-093328.
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Mizoguchi I, Chiba Y, Ohashi M, Xu M, Yoshimoto T. Expanding diversity in molecular structures and functions of the IL-6/IL-12 heterodimeric cytokine family. Front Immunol. 2016;7:479 eCollection. doi:10.3389/fimmu.2016.00479.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651–665. doi:10.1182/blood-2011-04-325225.
   PubMed Web of Science ®Google Scholar
• Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13:217–233. doi:10.1038/nrrheum.2017.22.
   PubMed Web of Science ®Google Scholar
• Croft M, Duan W, Choi H, Eun SY, Madireddi S, Mehta A. TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol. 2012;33:144–152. doi:10.1016/j.it.2011.10.004.
   PubMed Web of Science ®Google Scholar
• Al Dhahri H, Al Rubaie K, Hemachandran S, et al. Patterns of uveitis in a university-based tertiary referral center in Riyadh, Saudi Arabia. Ocul Immunol Inflamm. 2015;23:311–319. doi:10.3109/09273948.2014.939197.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol. 2013;91:e486–e493. doi:10.1111/aos.12127.
   PubMed Web of Science ®Google Scholar
• Standardization of Uveitis Nomenclature (SUN). Working Group: standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Murakami M, Kamimura D, Hirano T. New IL-6 (gp130) family cytokine members, CLC/NNT1/BSF3 and IL-27. Growth Factors. 2004;22:75–77.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243–1254.
   PubMed Web of Science ®Google Scholar
• Permyakov EA, Uversky VN, Permyakov SE. Interleukin-11: a Multifunctional Cytokine with Intrinsically Disordered Regions. Cell Biochem Biophys. 2016;74:285–296. doi:10.1007/s12013-016-0752-7.
   PubMed Web of Science ®Google Scholar
• Putoczki TL, Thiem S, Loving A, et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell. 2013;24:257–271. doi:10.1016/j.ccr.2013.06.017.
   PubMed Web of Science ®Google Scholar
• Johnstone CN, Chand A, Putoczki TL, Ernst M. Emerging roles for IL-11 signaling in cancer development and progression: focus on breast cancer. Cytokine Growth Factor Rev. 2015;26:489–498. doi:10.1016/j.cytogfr.2015.07.015.
   PubMed Web of Science ®Google Scholar
• Putoczki T, Ernst M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol. 2010;88:1109–1117. doi:10.1189/jlb.0410226.
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26:54–74. doi:10.1016/j.smim.2014.01.001.
   PubMed Web of Science ®Google Scholar
• Xu DH, Zhu Z, Wakefield MR, Xiao H, Bai Q, Fang Y. The role of IL-11 in immunity and cancer. Cancer Lett. 2016;373:156–163. doi:10.1016/j.canlet.2016.01.004.
   PubMed Web of Science ®Google Scholar
• Zhang X, Tao Y, Chopra M, et al. IL-11 Induces Th17 cell responses in patients with early relapsing-remitting multiple sclerosis. J Immunol. 2015;194:5139–5149. doi:10.4049/jimmunol.1401680.
   PubMed Web of Science ®Google Scholar
• Elshabrawy HA, Volin MV, Essani AB, et al. IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cells. Angiogenesis. 2018;21:215–228. doi:10.1007/s10456-017-9589-y.
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 1997;40:1096–1105. doi:10.1002/1529-0131(199706)40:6<1096::AID-ART13>3.0.CO;2-D.
   PubMed Web of Science ®Google Scholar
• Tang W, Geba GP, Zheng T, et al. Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, bronchial remodeling, and airways obstruction. J Clin Invest. 1996;98:2845–2853. doi:10.1172/JCI119113.
   PubMed Web of Science ®Google Scholar
• Kapina MA, Shepelkova GS, Avdeenko VG, et al. Interleukin-11 drives early lung inflammation during Mycobacterium tuberculosis infection in genetically susceptible mice. PLoS One. 2011;6:e21878. doi:10.1371/journal.pone.0021878.
   PubMed Web of Science ®Google Scholar
• Wong PK, Campbell IK, Robb L, Wicks IP. Endogenous IL-11 is pro-inflammatory in acute methylated bovine serum albumin/interleukin-1-induced (mBSA/IL-1)arthritis. Cytokine. 2005;29:72–76. doi:10.1016/j.cyto.2004.09.011.
   PubMed Web of Science ®Google Scholar
• Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210. doi:10.1002/path.2277.
   PubMed Web of Science ®Google Scholar
• Schafer S, Viswanathan S, Widjaja AA, et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature. 2017;552:110–115. doi:10.1038/nature24676.
   PubMed Web of Science ®Google Scholar
• Pathanapitoon K, Dodds EM, Cunningham ET Jr, Rothova A. Clinical Spectrum of HLA-B27-associated Ocular Inflammation. Ocul Immunol Inflamm. 2017;25:569–576. doi:10.1080/09273948.2016.1185527.
   PubMed Web of Science ®Google Scholar
• Yang P, Wan W, Du L, et al. Clinical features of HLA-B27-positive acute anterior uveitis with or without ankylosing spondylitis in a Chinese cohort. Br J Ophthalmol. 2018;102:215–219. doi:10.1136/bjophthalmol-2016-309499.
   PubMed Web of Science ®Google Scholar
• Bhattacharya P, Budnick I, Singh M, et al. Dual Role of GM-CSF as a Pro-Inflammatory and a regulatory cytokine: implications for immune therapy. J Interferon Cytokine Res. 2015;35:585–599. doi:10.1089/jir.2014.0149.
   PubMed Web of Science ®Google Scholar
• Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012;13:722–728. doi:10.1038/ni.2366.
   PubMed Web of Science ®Google Scholar
• Croxford AL, Kulig P, Becher B. IL-12-and IL-23 in health and disease. Cytokine Growth Factor Rev. 2014;25:415–421. doi:10.1016/j.cytogfr.2014.07.017.
   PubMed Web of Science ®Google Scholar
• Sawant DV, Hamilton K, Vignali DA. Interleukin-35: expanding Its Job Profile. J Interferon Cytokine Res. 2015;35:499–512. doi:10.1089/jir.2015.0015.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annu Rev Immunol. 2015;33:417–443. doi:10.1146/annurev-immunol-032414-112134.
   PubMed Web of Science ®Google Scholar
• Stohl W. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets. 2014;18:473–489. doi:10.1517/14728222.2014.888415.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10:365–373. doi:10.1038/nrrheum.2014.33.
   PubMed Web of Science ®Google Scholar
• Nakayamada S, Tanaka Y. BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflamm Regen. 2016;36:6. doi:10.1186/s41232-016-0015-4.
   PubMed Web of Science ®Google Scholar
• Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36:3–19. doi:10.1080/08830185.2016.1276903.
   PubMed Web of Science ®Google Scholar
• Lahiri A, Pochard P, Le Pottier L, et al. The complexity of the BAFF TNF-family members: implications for autoimmunity. J Autoimmun. 2012;39:189–198. doi:10.1016/j.jaut.2012.05.009.
   PubMed Web of Science ®Google Scholar
• Chen M, Lin X, Liu Y, et al. The function of BAFF on T helper cells in autoimmunity. Cytokine Growth Factor Rev. 2014;25:301–305. doi:10.1016/j.cytogfr.2013.12.011.
   PubMed Web of Science ®Google Scholar
• Kolfschoten GM, Pradet-Balade B, Hahne M, Medema JP. TWE-PRIL; a fusion protein of TWEAK and APRIL. Biochem Pharmacol. 2003;66:1427–1432.
   PubMed Web of Science ®Google Scholar
• Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A, et al. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus. 2016;25:582–592. doi:10.1177/0961203315608254.
   PubMed Web of Science ®Google Scholar
• Gø E, Nossent JC. APRIL levels strongly correlate with IL-17 in systemic lupus erythematosus. Lupus. 2014;23:1383–1391. doi:10.1177/0961203314543914.
   PubMed Web of Science ®Google Scholar
• Boghdadi G, Elewa EA. Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Rheumatol Int. 2014;34:1217–1223. doi:10.1007/s00296-014-3020-4.
   PubMed Web of Science ®Google Scholar
• Moura RA, Canhão H, Polido-Pereira J, et al. BAFF and TACI gene expression are increased in patients with untreated very early rheumatoid arthritis. J Rheumatol. 2013;40:1293–1302. doi:10.3899/jrheum.121110.
   PubMed Web of Science ®Google Scholar
• Wei F, Chang Y, Wei W. The role of BAFF in the progression of rheumatoid arthritis. Cytokine. 2015;76:537–544. doi:10.1016/j.cyto.2015.07.014.
   PubMed Web of Science ®Google Scholar
• Weldon AJ, Moldovan I, Cabling MG, et al. Surface APRIL is elevated on myeloid cells and is associated with disease activity in patients with rheumatoid arthritis. J Rheumatol. 2015;42:749–759. doi:10.3899/jrheum.140630.
   PubMedGoogle Scholar
• Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren‘s syndrome. Scand J Immunol. 2008;67:185–192. doi:10.1111/j.1365-3083.2007.02049.x.
   PubMed Web of Science ®Google Scholar
• Varin MM, Le Pottier L, Youinou P, Saulep D, Mackay F, Pers JO. B-cell tolerance breakdown in Sjögren‘s syndrome: focus on BAFF. Autoimmun Rev. 2010;9:604–608. doi:10.1016/j.autrev.2010.05.006.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Fujimoto M, Hasegawa M, et al. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol. 2007;34:2056–2062.
   PubMed Web of Science ®Google Scholar
• Bielecki M, Kowal K, Lapinska A, Bernatowicz P, Chyczewski L, Kowal-Bielecka O. Increased production of a proliferation-inducing ligand (APRIL) by peripheral blood mononuclear cells is associated with antitopoisomerase I antibody and more severe disease in systemic sclerosis. J Rheumatol. 2010;37:2286–2289. doi:10.3899/jrheum.100454.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 2006;54:192–201. doi:10.1002/(ISSN)1529-0131.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Hasegawa M, Matsushita Y, et al. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol. 2007;16:87–93. doi:10.1111/j.1600-0625.2006.00485.x.
   PubMed Web of Science ®Google Scholar
• Thangarajh M, Gomes A, Masterman T, Hillert J, Hjelmström P. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol. 2004;152:183–190. doi:10.1016/j.jneuroim.2004.03.017.
   PubMed Web of Science ®Google Scholar
• Thangarajh M, Masterman T, Rot U, et al. Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J Neuroimmunol. 2005;167:210–214. doi:10.1016/j.jneuroim.2005.06.024.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang K, Zhong X, et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol. 2012;32:1007–1011. doi:10.1007/s10875-012-9709-9.
   PubMed Web of Science ®Google Scholar
• Aziz HA, Flynn HW Jr, Young RC, Davis JL, Dubovy SR. Sympathetic ophthalmia: clinicopathologic correlation in a consecutive case series. Retina. 2015;35:1696–1703. doi:10.1097/IAE.0000000000000506.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Struyf S, Van Den Broeck C, et al. Expression of chemokines and gelatinase B in sympathetic ophthalmia. Eye. 2007;21:649–657. doi:10.1038/sj.eye.6702342.
   PubMed Web of Science ®Google Scholar
• Inomata H, Sakamoto T. Immunohistochemical studies of Vogt-Koyanagi-Harada disease with sunset sky fundus. Curr Eye Res. 1990;9:Suppl:35–40. doi:10.3109/02713689008999417.
   PubMed Web of Science ®Google Scholar
• Chan CC, Palestine AG, Kuwabara T, Nussenblatt RB. Immunopathologic study of Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1988;105:607–611.
   PubMed Web of Science ®Google Scholar
• Fazel SB, Howie SE, Krajewski AS, Lamb D. B lymphocyte accumulations in human pulmonary sarcoidosis. Thorax. 1992;47:964–967.
   PubMed Web of Science ®Google Scholar
• Krause P, Zahner SP, Kim G, Shaikh RB, Steinberg MW, Kronenberg M. The tumor necrosis factor family member TNFSF14 (LIGHT) is required for resolution of intestinal inflammation in mice. Gastroenterology. 2014;146:1752–1762. doi:10.1053/j.gastro.2014.02.010.
   PubMed Web of Science ®Google Scholar
• Petreaca ML, Do D, Dhall S, et al. Deletion of a tumor necrosis superfamily gene in mice leads to impaired healing that mimics chronic wounds in humans. Wound Repair Regen. 2012;20:353–366. doi:10.1111/j.1524-475X.2012.00785.x.
   PubMed Web of Science ®Google Scholar
• Petreaca ML, Yao M, Ware C, Martins-Green MM. Vascular endothelial growth factor promotes macrophage apoptosis through stimulation of tumor necrosis factor superfamily member 14 (TNFSF14/LIGHT). Wound Repair Regen. 2008;16:602–614. doi:10.1111/j.1524-475X.2008.00411.x.
   PubMed Web of Science ®Google Scholar
• Maña P, Liñares D, Silva DG, et al. LIGHT (TNFSF14/CD258) is a decisive factor for recovery from experimental autoimmune encephalomyelitis. J Immunol. 2013;191:154–163. doi:10.4049/jimmunol.1203016.
   PubMed Web of Science ®Google Scholar